Global Juvenile Macular Degeneration (Stargardt Disease) Market: Information by Diagnosis (Fluorescein Angiography and others), Management (Magnifying Spectacles and others), End User (Hospital & Eye Clinics and others) and Region - Forecast till 2027

Market Overview

The Global Juvenile Macular Degeneration (Stargardt Disease) Market is expected to register a CAGR of 6.7% and is anticipated to reach USD 1593.885 million by 2027. 

Juvenile macular degeneration is a genetic eye disorder that causes progressive vision loss. This disorder affects the retina, the specialized light-sensitive tissue that lines the back of the eye. Specifically, juvenile macular degeneration affects a small area near the center of the retina called the macula. The macula is responsible for sharp central vision, which is needed for detailed tasks such as reading, driving, and recognizing faces. The market is mainly driven by factors such as the increasing prevalence of eye disorders, development of new drugs and therapies, and emerging government policies. However, the high cost of treatment and lack of reimbursement is expected to restrain the growth of this market.

Market Dynamics

The rising prevalence of eye disorder and technological advancements in juvenile macular degeneration are some of the factors that drive the growth of the market. Juvenile macular degeneration is a rare inherited eye condition which affects the central area of the retina called the macula, also known as fundus flavimaculatus. It affects about 1 in 10,000 people and is sometimes called juvenile macular dystrophy since it tends to first appear between the ages of 10 to 20 although visual impairment may not be apparent until as late as ages 30 to 40. Juvenile macular degeneration disease causes parts of the macula to stop working, leading to problems with central vision, detailed vision, and sometimes with color perception. The major driving factors for the global juvenile macular degeneration market are increasing the prevalence of eye disorders, development of new drugs, and therapies, and emerging government policies. However, lack of awareness and no treatment option for juvenile macular dystrophy may hamper the market growth.

Global Juvenile Macular Degeneration (Stargardt Disease) Market Size, by Diagnosis, 2016 and 2027 (USD Million)  

Source: MRFR Analysis

Segmentation

The global juvenile macular degeneration (Stargardt disease) market has been segmented into diagnosis, management, and end user. Based on the diagnosis, the market has been segregated into fluorescein angiography (FA), fundus autofluorescence (FAF), optical coherence tomography (OCT), and electroretinography (ERG). The FA segment accounted for a market value of USD 270.110 million in 2016. Based on management, the market has been segregated into magnifying spectacles, magnifiers, and reading telescopes. The global juvenile macular degeneration (Stargardt disease) market on the basis of end-user is divided into hospital & eye clinics, and research & academic institutes.

Key Players

The prominent players in the global juvenile macular degeneration (Stargardt disease) market are Astellas Pharma Inc (Japan), Sanofi (France), Acucela Inc (Japan), Alkeus Pharma (US), Copernicus Therapeutics (US), Ophthotech Corporation (US), Bayer AG (Germany), Oxford BioMedica PLC (UK), and Grupo Ferrer (Spain).

Some of the key strategies followed by the players operating in the global juvenile macular degeneration (Stargardt disease) market were innovation, product development, acquisition, mergers, and expansion.

Global Juvenile Macular Degeneration (Stargardt Disease) Market Share, by Region, 2016 (%)  

Source: MRFR Analysis

Regional Analysis

The global juvenile macular degeneration (Stargardt disease) market, based on region, is divided into the Americas, Europe, Asia-Pacific, and the Middle East & Africa.

Europe accounted for the significant share in the market for juvenile macular degeneration. Rising investment in research & development, well-developed healthcare infrastructure, and increasing healthcare funds are some of the factors responsible for boosting the growth of the market in this region. Europe held the most significant market share of 32.7 % in 2016.

Americas is estimated to be the second-largest market. This is attributed due to the well-developed technology, rising healthcare expenditure, and the presence of the leading players in the market.

Asia-Pacific is projected to be the fastest-growing market due to the rising aging population, increasing healthcare expenditure, and rapidly changing healthcare sector. In addition to this, improving healthcare facilities and rising economic growth is positively impacting the market growth in this region.

The market in the Middle East & Africa is expected to witness steady growth due to increasing investments in research & development, well-developed infrastructure, and advancement in technology.

Key Updates

• In November 2017, Astellas Pharma Inc launched “Repatha” a human monoclonal antibody for the treatment of hypercholesterolemia.

• In December 2017, Sanofi acquired Protein Science company in order to expand its product portfolio.

• In January 2017, Acucela Inc received orphan drug approval for treatment of Stargardt disease. Hence this product approval will help the company to increase its revenue in the future as very few drugs are available for the treatment of Stargardt disease.

Market Segmentation

Global Juvenile Macular Degeneration (Stargardt Disease) Market, by Diagnosis

• Fluorescein Angiography (FA)


• Fundus Autofluorescence (FAF)


• Optical Coherence Tomography (OCT)


• Electroretinography (ERG)

Global Juvenile Macular Degeneration (Stargardt Disease) Market, by Management

• Magnifying Spectacles


• Magnifiers


• Reading telescopes     

Global Juvenile Macular Degeneration (Stargardt Disease) Market, by End-User

• Hospital & Eye Clinics


• Research & Academic Institutes

Global Juvenile Macular Degeneration (Stargardt Disease) Market, by Region

• 
  Americas
  
  
  
  • 
    North America
    
    
    
    • US
    
    
    • Canada
    
    
    
    
  
  
  • Latin America
  
  
  
  

• 
  Europe
  
  
  
  • 
    Western Europe
    
    
    
    • Germany
    
    
    • UK
    
    
    • France
    
    
    • Italy
    
    
    • Spain
    
    
    • Rest of Western Europe
    
    
    
    
  
  
  • Eastern Europe
  
  
  
  

• 
  Asia-Pacific
  
  
  
  • China
  
  
  • Japan
  
  
  • India
  
  
  • Australia
  
  
  • South Korea
  
  
  • Rest of Asia-Pacific
  
  
  
  

• 
  Middle East & Africa
  
  
  
  • Middle East
  
  
  • Africa
  
  
  
  

Available Additional Customizations

Intended Audience

• Medical device manufacturers and distributors


• Government research organizations


• Hospitals and clinics


• Regulatory agencies


• Contract research organizations


• Pharmaceutical companies


• Medical research laboratories